InvestorsHub Logo
Followers 9
Posts 1462
Boards Moderated 0
Alias Born 07/20/2012

Re: Evaluate post# 21039

Saturday, 10/11/2014 12:23:52 PM

Saturday, October 11, 2014 12:23:52 PM

Post# of 704077
Although there was an improvement in progression-free survival, it could not be considered clinically relevant because of limitations in the methods available to measure the size of brain tumors.

I don't like the sounds of that at all. Does NWBO face a risk of the FDA taking the same position on their clinical trial end point?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News